For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

Kazia Therapeutics (KZIA) announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium, or SABCS, providing ...

Kazia Therapeutics Limited ("Kazia" or the "Company")  today announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium (SABCS) providing compelling mechanistic and ...

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer ...

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and ...

The liver plays a central role in maintaining systemic energy homeostasis during fasting by mobilizing lipid reserves, a ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the ...

PROVIDENCE, R.I. [Brown University] - Interrupting one function of a protein that plays a key role in cell signaling could ...

Montara Therapeutics Announces Development Candidate for First BrainOnly™-Enabled Program in TSC-Related Epilepsy and ...

Sapu003 is a novel intravenous nanoparticle formulation of everolimus engineered using Sapu Nano’s proprietary Deciparticle ™ technology. It is designed to overcome the poor bioavailability, ...